Combi-nation studies of other HDAC inhibitors observed inhibition of the CML K-562 cell line by a combination of dasatinib with the class I HDAC inhibitor MS-275 (entinostat) [113], and of thyroid cancer cell lines with dasatinib combinations with pan-histone inhibitors belinostat or panobinostat [114]. Here, HDAC9 is linked to thyroid cancer.